Tomomura M, Tomomura A. Caldecrin: A pancreas-derived hypocalcemic factor, regulates osteoclast formation and function. World J Biol Chem 2015; 6(4): 358-365 [PMID: 26629319 DOI: 10.4331/wjbc.v6.i4.358]
Corresponding Author of This Article
Mineko Tomomura, PhD, Associate Professor, Meikai Pharmaco-Medical Laboratory, MPL and Division of Biochemistry, Department of Oral Biology and Tissue Engineering, Meikai University School of Dentistry, 1-1 Keyakidai, Sakado, Saitama 350-0283, Japan. mineko-t@dent.meikai.ac.jp
Research Domain of This Article
Biochemistry & Molecular Biology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Biol Chem. Nov 26, 2015; 6(4): 358-365 Published online Nov 26, 2015. doi: 10.4331/wjbc.v6.i4.358
Caldecrin: A pancreas-derived hypocalcemic factor, regulates osteoclast formation and function
Mineko Tomomura, Akito Tomomura
Mineko Tomomura, Meikai Pharmaco-Medical Laboratory, MPL and Division of Biochemistry, Department of Oral Biology and Tissue Engineering, Meikai University School of Dentistry, Sakado, Saitama 350-0283, Japan
Akito Tomomura, Division of Biochemistry, Department of Oral Biology and Tissue Engineering, Meikai University School of Dentistry, Sakado, Saitama 350-0283, Japan
Author contributions: Tomomura M and Tomomura A contributed equally to the writing of the manuscript.
Conflict-of-interest statement: The authors declare no conflict of interest associated with this manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Mineko Tomomura, PhD, Associate Professor, Meikai Pharmaco-Medical Laboratory, MPL and Division of Biochemistry, Department of Oral Biology and Tissue Engineering, Meikai University School of Dentistry, 1-1 Keyakidai, Sakado, Saitama 350-0283, Japan. mineko-t@dent.meikai.ac.jp
Telephone: +81-49-2792766 Fax: +81-49-2712503
Received: May 29, 2015 Peer-review started: May 30, 2015 First decision: August 7, 2015 Revised: September 1, 2015 Accepted: September 29, 2015 Article in press: September 30, 2015 Published online: November 26, 2015 Processing time: 178 Days and 16.5 Hours
Core Tip
Core tip: Caldecrin (also known as chymotrypsin C) reduces serum calcium levels. This activity is distinct from its protease activity but also requires trypsin-mediated cleavage of the pro-peptide, converting caldecrin to its active form. Ectopic intramuscular expression of caldecrin prevented bone resorption in ovariectomized mice. Caldecrin inhibited parathyroid hormone-stimulated calcium release from fetal mouse long bones. Furthermore, caldecrin suppressed receptor activator of nuclear factor-kappa B ligand-induced activation of intracellular calcium signaling, thereby reducing osteoclast formation and bone resorption. Caldecrin is a unique multifunctional protease that possesses anti-osteoclastogenic activity, resulting in reduced serum calcium levels.
